Prediction of suboptimal cytoreduction of epithelial ovarian carcinoma by preoperative computed tomography

In an aim to evaluate the diagnostic efficacy of preoperative abdominal-pelvic CT for the prediction of suboptimal cytoreduction of epithelial ovarian carcinoma (EOC) at primary surgery, CT scans of 48 patients who underwent primary surgery for EOC were retrospectively analyzed. The presence of at least one of the following CT findings: multiple implants > 1 cm in maximum diameter in the mesenteria of the small or large intestines, porta hepatis or intersegmental fissure or on the hepatic surface, diaphragmatic peritoneum, gastrohepatic or gastrosplenic ligaments or the extension of tumor infiltration > 2 cm on the omentum towards the spleen or stomach or the intestines encased by the tumor > 2 cm, diffuse peritoneal thickening or invasion of the lateral pelvic wall > 1 cm or multiple lymph nodes > 1 cm at the cardiophrenic and suprarenal levels were accepted as the critical markers for predicting suboptimal cytoreduction. Suboptimal surgery, defined as leaving a residual tumor mass > 1 cm, was determined in 18 (37.5%) patients. CT predicted suboptimal cytoreduction with 83.3% (15/18) sensitivity, 90% (27/30) specificity and 87.5% (42/48) accuracy. PPV and NPV values were 83.3% (15/18) and 90% (27/30), respectively. These results suggested that preoperative CT could successfully predict suboptimal surgery in patients with EOC.

Ovarian carcinoma; Cytoreduction; Computed tomography.

[1] Landis S.H., Murray T., Bolden S., Wingo P.A.: “Cancer statistics, 1998”. CA Cancer J. Clin., 1998, 48, 6.

[2] Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E. et al.: “Cancer statistics 2004”. CA Cancer J. Clin., 2004, 54, 8.

[3] Pecorrelli S., Benedet J.L., Creasman W.T., Shaperd J.H.: “FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics”. Int. J. Gynaecol. Obstet., 1999, 64, 5.

[4] Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A.: “The influ-ence of cytoreductive surgery on recurrence-free interval and sur-vival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1992, 47, 159.

[5] Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M. et al.: “The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma”. Am. J. Obstet. Gynecol., 1994, 170, 974.

[6] Omura G.A., Brady M.F., Homesley H.D., Yordan E., Major F.J., Buchsbaum H.J. et al.: “Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience”. J. Clin. Oncol., 1991, 9, 1138.

[7] Dowdy S.C., Mullany S.A., Brandt K.R., Huppert B.J., Cliby W. A.: “The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma”. Cancer, 2004, 101, 346.

[8] Bristow R.E., Duska L.R., Lambrou N.C., Fishman E.K., O’Neill M. J., Trimble E.L. et al.: “A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography”. Cancer, 2000, 89, 1532.

[9] Seifer D.B., Kennedy A.W., Webster K.D., Vanderbrug Medendorp S., Isakson D.G.: “Outcome of primary cytoreductive surgary advanced epithelial ovarian carcinoma”. Cleve Clin. J. Med., 1988, 55, 555.

[10] Hoskins W.J.: “Epithelial ovarian carcinoma: principles of primary surgery”. Gynecol. Oncol., 1994, 55, 91.

[11] Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., Van Dam P.: “Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients”. Gynecol. Oncol., 1998, 71, 431.

[12] Eisenkop S.M., Friedman R.L., Wang H.J.: “Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study”. Gynecol. Oncol., 1998, 69, 103.

[13] Hoskins W.J.: “The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer”. Bail-lieres Clin Obstet Gynaecol., 1989, 3, 59.

[14] Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.L., Thiel R. P.: “Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival”. Gynecol. Oncol., 1999, 72, 93.

[15] Vergote I.B., De Wever I., Decloedt J., Tjalma W., Van Gramberen M., van Dam P.: “Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer”. Semin. Oncol., 2000, 27, 31.

[15]

Meyer J.I., Kennedy A.W., Friedman R., Ayoub A., Zepp R.C.: “Ovarian carcinoma: value of CT in predicting success of debulking surgery”. AJR Am. J. Roentgenol., 1995, 165, 875.

[15]

Nelson B.E., Rosenfield A.T., Schwartz P.E.: “Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma”. J. Clin. Oncol., 1993, 11, 166.

[18] Qayyum A., Coakley F.V., Westphalen A.C., Hricak H., OkunoW. T., Powell B.: “Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer”. Gynecol. Oncol., 2005, 96, 301.

[19] Byrom J., Widjaja E., Redman C.W.E., Jones P.W., Tebby S.: “Can preoperative computed tomography predict resectability of ovarian carcinoma at primary laparotomy?”. BJOG, 2002, 109, 369.

[20] Schwartz P.E., Chambers J.T., Makuch R.: “Neoadjuvant chemotherapy for advanced ovarian cancer”. Gynecol. Oncol., 1994, 53, 33.

[21] Fanfani F., Ferrandina G., Corrado G., Fagotti A., Zakut H.V., Mancuso S. et al.: “Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO Stage IIIC ovarian cancer patients”. Oncology, 2003, 65, 316.

[22] Morice P., Dubernard G., Rey A., Atallah D., Pautier P., Pomel C. et al.: “Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer”. J. Am. Coll. Surg., 2003, 197, 955.

[23] Aletti G.D., Gostout B.S., Podratz K.C., Cliby W.A.: “Ovarian cancer resectability: relative impact of disease, patient status, and surgeon”. Gynecol. Oncol., 2006, 100, 33.

[24] Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S. et al.: “Multi-institutional reciprocal validation study of computed tomography predictors suboptimal primary cytoreduction in patients with advanced ovarian cancer”. J. Clin. Oncol., 2007, 25, 384.